Historical patterns indicate that abrupt fluctuations in the market can impact any firm, regardless of its seeming dominance.

NEW YORK, Feb 10 (Reuters) - Pfizer ‌agreed ​to accept $29 million to ‌resolve a dispute with the U.S. Securities and ...

Pfizer on Tuesday released trial data on a high-profile obesity drug from its recent $10 billion Metsera purchase that raises questions about its tolerability for patients, and shares of the U.S.

Pfizer targets 2028 for its first obesity drug approval Company plans to advance more than 20 obesity trials in 2026 RSV vaccine quarterly sales top expectations Feb 3 (Reuters) - Pfizer (PFE.N), ...

Feb 3 (Reuters) - Pfizer on Tuesday released trial data on a high-profile ‌obesity drug from its recent $10 billion Metsera purchase that raises ‌questions about its tolerability for patients, and ...

Pfizer is one of the world's largest pharmaceutical companies. It has a long history of navigating the competitive and technically complex industry. Pfizer's stock has lost half its value since late ...

Whereas conventional treatments such as chemotherapy and radiotherapy show their limitations in battling certain advanced cancers, immunotherapy and therapeutic vaccines have opened up a new realm of ...

Consumer advocacy organization Public Citizen has filed (PDF) a Freedom of Information Act (FOIA) lawsuit against the Department of Health and Human Services (HHS) and the Department of Commerce (DOC) ...

In the last six months Pfizer’s stock (NYSE: PFE) has underperformed Merck (NYSE: MRK) and Johnson & Johnson (NYSE: JNJ) primarily due to waning demand for its COVID-19 products, a significant ...

Top executives from drugmakers big and small told CNBC that the next phase of the obesity drug market will be defined by a broader range of treatment options and improved access for patients. CNBC ...